Featured Research

from universities, journals, and other organizations

Study Shows Common Painkillers Combined With Acid-Reducing Drugs More Cost-Effective, Safer For Managing Arthritis In High-Risk Patients

Date:
April 12, 2005
Source:
University Of California Los Angeles
Summary:
Amid the recent controversy and confusion over serious side effects from pain medications, a new UCLA and Veterans Affairs Greater Los Angeles Healthcare System study demonstrates that for arthritis sufferers at high risk for gastrointestinal problems who traditionally may have used a drug like Vioxx, the most cost-effective and safest treatment is actually a common painkiller combined with an acid-reducing drug.

Amid the recent controversy and confusion over serious side effects from pain medications, a new UCLA and Veterans Affairs Greater Los Angeles Healthcare System study demonstrates that for arthritis sufferers at high risk for gastrointestinal problems who traditionally may have used a drug like Vioxx, the most cost-effective and safest treatment is actually a common painkiller combined with an acid-reducing drug.

Published in the April 15 issue of Arthritis Care and Research, the clinical journal of the American College of Rheumatology, the study used a sophisticated economic model to develop patient scenarios and compare costs of the following three therapies often used for treating pain from chronic arthritis: 1) a nonsteroidal anti-inflammatory drug alone, such as Naproxen or Ibuprofen; 2) a nonsteroidal anti-inflammatory drug combined with an acid-reducing drug (proton pump inhibitor) such as Prevacid or Nexium; and 3) a Cox-2 inhibitor (cyclooxygenase 2-selective inhibitor) alone, such as Vioxx or Celebrex.

The study marks the first time researchers have looked at the cost-effectiveness of a popular combination of two drugs and also included other factors that may affect therapy, such as aspirin use and the risk of complications such as heart attack.

According to researchers, the study also looked at the health economic consequences of heart attacks related to Cox-2 inhibitors like Vioxx. The study, completed a year before Vioxx was removed from the market, not only predicted the cardiovascular complications, but also demonstrated that a combination therapy of two other drugs may prove more cost-effective and safer than Cox-2s.

"The study is one of the first to assess the most relevant therapies for high-risk arthritis patients," said Dr. Brennan M.R. Spiegel, study author and co-director, Center for the Study of Digestive Healthcare Quality and Outcomes and assistant professor of medicine, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System. "We found that for high-risk patients, the combination of a common anti-inflammatory drug taken with an acid‑lowering drug was not only less expensive, but also safer and more effective. Cox-2 inhibitors were not a health economic bargain at all — especially given the added costs of more heart attacks."

More than 15 million Americans suffer from chronic arthritis, including osteoarthritis and rheumatoid arthritis. According to researchers, non-steroidal anti-inflammatory drugs are the most commonly used medications for chronic arthritis, but can cause gastrointestinal complications such as ulcers and hemorrhages in high-risk patients.

The UCLA study found that for high-risk patients, it is more cost-effective and safer to use a non-steroidal anti-inflammatory drug combined with a proton pump inhibitor, which is an acid-lowering drug, compared to using a Cox-2 inhibitor drug alone, which guidelines had traditionally recommended as a first-line therapy for this patient group. According to the study, for patients at low risk of gastrointestinal problems, a non-steroidal anti-inflammatory drug alone proved the most cost-effective.

Over a one-year timeframe, researchers tracked a hypothetical group of 60-year-old patients with chronic arthritis who require long-term non-steroidal anti-inflammatory drug therapy for moderate to severe arthritis pain. Since this is an older group, it was assumed that some patients were taking a daily aspirin for cardiovascular benefits.

"With an aging population that will have higher risk factors for gastrointestinal and other health events, it's critical to assess arthritis therapies using additional factors that can impact treatment such as taking aspirin," Spiegel said.

The model reflected probabilities of various adverse events that could occur, including heart attack, ulcer perforation, ulcer bleeds and stomachaches. Medical and hospital costs for these events were factored into the cost analysis. Researchers used a standard measure that assesses the outcome of health care procedures or services called the quality-adjusted life-year. The measurement is designed to take into account health-related quality of life as well as the duration of survival.

The study was funded by Tap Pharmaceutical Products Inc., manufacturer of lansoprazole, which is marketed under the brand name Prevacid.

In addition to Spiegel, other researchers included Chiun-Fang Chiou and Dr. Joshua J. Ofman, Cerner Health Insights, Beverly Hills, Calif.


Story Source:

The above story is based on materials provided by University Of California Los Angeles. Note: Materials may be edited for content and length.


Cite This Page:

University Of California Los Angeles. "Study Shows Common Painkillers Combined With Acid-Reducing Drugs More Cost-Effective, Safer For Managing Arthritis In High-Risk Patients." ScienceDaily. ScienceDaily, 12 April 2005. <www.sciencedaily.com/releases/2005/04/050411211308.htm>.
University Of California Los Angeles. (2005, April 12). Study Shows Common Painkillers Combined With Acid-Reducing Drugs More Cost-Effective, Safer For Managing Arthritis In High-Risk Patients. ScienceDaily. Retrieved April 20, 2014 from www.sciencedaily.com/releases/2005/04/050411211308.htm
University Of California Los Angeles. "Study Shows Common Painkillers Combined With Acid-Reducing Drugs More Cost-Effective, Safer For Managing Arthritis In High-Risk Patients." ScienceDaily. www.sciencedaily.com/releases/2005/04/050411211308.htm (accessed April 20, 2014).

Share This



More Health & Medicine News

Sunday, April 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Nine-Month-Old Baby Can't Open His Mouth

Nine-Month-Old Baby Can't Open His Mouth

Newsy (Apr. 19, 2014) Nine-month-old Wyatt Scott was born with a rare disorder called congenital trismus, which prevents him from opening his mouth. Video provided by Newsy
Powered by NewsLook.com
'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Little Progress Made In Fighting Food Poisoning, CDC Says

Little Progress Made In Fighting Food Poisoning, CDC Says

Newsy (Apr. 18, 2014) A new report shows rates of two foodborne infections increased in the U.S. in recent years, while salmonella actually dropped 9 percent. Video provided by Newsy
Powered by NewsLook.com
Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins